These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients. Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027 [TBL] [Abstract][Full Text] [Related]
7. Germline sequencing for presumed germline pathogenic variants via tumor-only comprehensive genomic profiling. Kondo T; Yamamoto Y; Fukuyama K; Kanai M; Yamada A; Matsubara J; Quy PN; Yoshioka M; Yamada T; Minamiguchi S; Matsumoto S; Kosugi S; Muto M Int J Clin Oncol; 2022 Aug; 27(8):1256-1263. PubMed ID: 35567649 [TBL] [Abstract][Full Text] [Related]
8. Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors. Cobain EF; Wu YM; Vats P; Chugh R; Worden F; Smith DC; Schuetze SM; Zalupski MM; Sahai V; Alva A; Schott AF; Caram MEV; Hayes DF; Stoffel EM; Jacobs MF; Kumar-Sinha C; Cao X; Wang R; Lucas D; Ning Y; Rabban E; Bell J; Camelo-Piragua S; Udager AM; Cieslik M; Lonigro RJ; Kunju LP; Robinson DR; Talpaz M; Chinnaiyan AM JAMA Oncol; 2021 Apr; 7(4):525-533. PubMed ID: 33630025 [TBL] [Abstract][Full Text] [Related]
9. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. Mandelker D; Zhang L; Kemel Y; Stadler ZK; Joseph V; Zehir A; Pradhan N; Arnold A; Walsh MF; Li Y; Balakrishnan AR; Syed A; Prasad M; Nafa K; Carlo MI; Cadoo KA; Sheehan M; Fleischut MH; Salo-Mullen E; Trottier M; Lipkin SM; Lincoln A; Mukherjee S; Ravichandran V; Cambria R; Galle J; Abida W; Arcila ME; Benayed R; Shah R; Yu K; Bajorin DF; Coleman JA; Leach SD; Lowery MA; Garcia-Aguilar J; Kantoff PW; Sawyers CL; Dickler MN; Saltz L; Motzer RJ; O'Reilly EM; Scher HI; Baselga J; Klimstra DS; Solit DB; Hyman DM; Berger MF; Ladanyi M; Robson ME; Offit K JAMA; 2017 Sep; 318(9):825-835. PubMed ID: 28873162 [TBL] [Abstract][Full Text] [Related]
10. Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. Meric-Bernstam F; Brusco L; Daniels M; Wathoo C; Bailey AM; Strong L; Shaw K; Lu K; Qi Y; Zhao H; Lara-Guerra H; Litton J; Arun B; Eterovic AK; Aytac U; Routbort M; Subbiah V; Janku F; Davies MA; Kopetz S; Mendelsohn J; Mills GB; Chen K Ann Oncol; 2016 May; 27(5):795-800. PubMed ID: 26787237 [TBL] [Abstract][Full Text] [Related]
11. TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy. Gray PN; Vuong H; Tsai P; Lu HM; Mu W; Hsuan V; Hoo J; Shah S; Uyeda L; Fox S; Patel H; Janicek M; Brown S; Dobrea L; Wagman L; Plimack E; Mehra R; Golemis EA; Bilusic M; Zibelman M; Elliott A Oncotarget; 2016 Oct; 7(42):68206-68228. PubMed ID: 27626691 [TBL] [Abstract][Full Text] [Related]
12. Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing. Cheng DT; Prasad M; Chekaluk Y; Benayed R; Sadowska J; Zehir A; Syed A; Wang YE; Somar J; Li Y; Yelskaya Z; Wong D; Robson ME; Offit K; Berger MF; Nafa K; Ladanyi M; Zhang L BMC Med Genomics; 2017 May; 10(1):33. PubMed ID: 28526081 [TBL] [Abstract][Full Text] [Related]
13. Sequencing paired tumor DNA and white blood cells improves circulating tumor DNA tracking and detects pathogenic germline variants in localized colon cancer. Gimeno-Valiente F; Martín-Arana J; Tébar-Martínez R; Gambardella V; Martínez-Ciarpaglini C; García-Micó B; Martínez-Castedo B; Palomar B; García-Bartolomé M; Seguí V; Huerta M; Moro-Valdezate D; Pla-Martí V; Pérez-Santiago L; Roselló S; Roda D; Cervantes A; Tarazona N ESMO Open; 2023 Dec; 8(6):102051. PubMed ID: 37951129 [TBL] [Abstract][Full Text] [Related]
14. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study. Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984 [TBL] [Abstract][Full Text] [Related]
15. Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study. Casula M; Paliogiannis P; Ayala F; De Giorgi V; Stanganelli I; Mandalà M; Colombino M; Manca A; Sini MC; Caracò C; Ascierto PA; Satta RR; ; Lissia A; Cossu A; Palmieri G; BMC Cancer; 2019 Aug; 19(1):772. PubMed ID: 31382929 [TBL] [Abstract][Full Text] [Related]
16. Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping. Zugazagoitia J; Ramos I; Trigo JM; Palka M; Gómez-Rueda A; Jantus-Lewintre E; Camps C; Isla D; Iranzo P; Ponce-Aix S; García-Campelo R; Provencio M; Franco F; Bernabé R; Juan-Vidal O; Felip E; de Castro J; Sanchez-Torres JM; Faul I; Lanman RB; Garrido P; Paz-Ares L Ann Oncol; 2019 Feb; 30(2):290-296. PubMed ID: 30535340 [TBL] [Abstract][Full Text] [Related]
17. Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing. Terraf P; Pareja F; Brown DN; Ceyhan-Birsoy O; Misyura M; Rana S; O'Reilly E; Carlo MI; Aghajanian C; Liu Y; Derakhshan F; Jayakumaran G; Weigelt B; Walsh M; Stadler Z; Offit K; Ladanyi M; Robson M; Zehir A; Reis-Filho JS; Mandelker D Ann Oncol; 2022 Apr; 33(4):426-433. PubMed ID: 35074424 [TBL] [Abstract][Full Text] [Related]
18. Using circulating cell-free DNA to monitor personalized cancer therapy. Oellerich M; Schütz E; Beck J; Kanzow P; Plowman PN; Weiss GJ; Walson PD Crit Rev Clin Lab Sci; 2017 May; 54(3):205-218. PubMed ID: 28393575 [TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis of germline mutations in northern Brazil: a panel of 16 genes for hereditary cancer-predisposing syndrome investigation. Vidal AF; Ferraz RS; El-Husny A; Silva CS; Vinasco-Sandoval T; Magalhães L; Raiol-Moraes M; Barra WF; Pereira CLBL; de Assumpção PP; de Brito LM; Vialle RA; Santos S; Ribeiro-Dos-Santos Â; Ribeiro-Dos-Santos AM BMC Cancer; 2021 Apr; 21(1):363. PubMed ID: 33827469 [TBL] [Abstract][Full Text] [Related]
20. Frequency of actionable germline pathogenic variants identified through tumor next-generation sequencing in a gynecologic cancer cohort. Karpel H; Manderski E; Pothuri B Int J Gynecol Cancer; 2023 Jul; 33(7):1044-1050. PubMed ID: 36889816 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]